A Phase 3 interventional study of lamictal in Bipolar Disorder, sponsored by GlaxoSmithKline. Completed at 46 sites in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-01-09.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing lamotrigine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Lamotrigine · Bipolar Disorder.
Among the 33 studies testing lamotrigine in Bipolar Disorder, this one is the 4th largest by enrollment, is one of 4 that started in 2008, is one of 11 in phase 3, and was the 23rd registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 33 studies testing lamotrigine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 301 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 72 across the 33 interventional studies. Of the 33 that completed or were terminated, 20 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 33 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
17 studies in Bipolar Disorder by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 17 finished, 6 (35%) have results posted.
Among the 17 studies in Bipolar Disorder by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2008, is one of 7 in phase 3, and was the 11th registered.
GlaxoSmithKline’s Bipolar Disorder studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing lamotrigine in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 17 in Bipolar Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will be a multi-center, parallel, group, placebo control, double-blind, randomized controlled trial of lamictal as add-on maintenance treatment in pediatric outpatients (aged 10 to 17 years) diagnosed with Bipolar I disorder. The study consists of 4 phases: Screen (approximately 2 weeks), Open label phase (up to 18 weeks), Randomized phase (up to 36 weeks) and Taper and follow-up phase (up to 4 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Controlled
Drug: lamictal
Flexible Dosing
Drug: lamictal
Flexible Dosing
Time From Randomization to the Occurrence of a Bipolar Event (TOBE)
TOBE was defined by the first prescription of any additional pharmacotherapy to treat bipolar symptoms, increasing the dose(s) of the participants conventional bipolar medication(s), treatment with electroconvulsive therapy, or moving the participant to a more restricted environment for observation, safety, or treatment; or participant withdrawal from the study due to a bipolar-related adverse event (AE) or serious adverse event (SAE); or participants withdrawal from the study due to lack of efficacy as defined by rating scale threshold scores. TOBE was calculated using a log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).
Time frame: From randomization until Week 36
Time From Randomization to Withdrawal From the Study for Any Cause (TTW)
The time from randomization to the withdrawal from study was analyzed. TTW was calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).
Time frame: From randomization until withdrawal from the study for any cause (up to Week 36)
Time From Randomization to Intervention for a Mood Episode (TIME)
The time from randomization to the intervention for a mood episode (depression, mania/hypomania or mixed mood) was analyzed. TIME was calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).
Time frame: From randomization until intervention administered for a mood episode (up to Week 36)
Time From Randomization to Intervention for Depression (TIDep), Mania/Hypomania (TIMan), or a Mixed Episode (TIMix)
The time from randomization to intervention for depression (TIDep), mania/hypomania (TIMan), or a mixed episode (TIMix) was analyzed. TIDep, TIMan, and TIMix were calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).
Time frame: From randomization until intervention administered for depression, mania/hypomania or a mixed episode (up to Week 36)
Number of Participants Experiencing a Relapse/Recurrence to Depression, Mania/Hypomania, or Mixed Mood State
The number of participants requiring intervention to treat either the emergence of or a change in bipolar symptoms that is, experiencing a relapse/recurrence to depression, mania/hypomania, or mixed mood state were analyzed.
Time frame: From randomization until a relapse/recurrence to depression, mania/hypomania, or mixed mood state (up to Week 36)
Number of Participants Experiencing a Relapse/Recurrence Within the First 30, 90, and 180 Days in the Randomized Phase
The proportion of participants (par.) requiring intervention to treat either the emergence of or a change in bipolar symptoms, that is, experiencing a relapse/recurrence to depression, mania/hypomania, or mixed mood state at any time within the first 30, 90, and 180 days in the Randomized Phase were analyzed.
Time frame: From randomization up to Week 36
Change From Baseline in the Quick Inventory of Depressive Symptomatology - Clinician Interview, Semi-structured, Adolescent Version (QIDS- A17-C) at Each Visit in the Open-Label Phase
The QIDS-A17-C is a 17-item scale used to assess depression severity in adolescents according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). Analysis was performed using mixed model repeated measures.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
Change From Randomization in the Quick Inventory of Depressive Symptomatology - Clinician Interview, Semi-structured, Adolescent Version (QIDS- A17-C) at Each Visit in the Randomized Phase
The QIDS-A17-C is a 17-item scale used to assess depression severity in adolescents according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). Analysis was performed using mixed model repeated measures.
Time frame: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self-report Adolescent Version (QIDS-A17-SR) at Each Visit in the Open-Label Phase
The QIDS-A17-SR is a 17-item scale used to assess depression severity in adolescents according to the DSM-IV-TR diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). The scale is completed by the participant. Analysis was performed using mixed model repeated measures.
Time frame: Baseline and Weeks 4, 8, 12, 16, and 18
Change From Randomization in the Quick Inventory of Depressive Symptomatology - Self-report Adolescent Version (QIDS-A17-SR) at Each Visit in the Randomized Phase
The QIDS-A17-SR is a 17-item scale used to assess depression severity in adolescents according to the DSM-IV-TR diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). The scale is completed by the participant. Analysis was performed using mixed model repeated measures.
Time frame: Randomization and Weeks 8, 16, 24, 32, and 36
Change From Baseline in the Clinical Global Impressions - Bipolar, Severity of Illness (CGI-BP[S]) at Each Visit in the Open-Label Phase
Severity of the bipolar illness was based on the CGI-BP(S) score which had a range from 1 (normal, not ill) to 7 (very severely ill). Analysis was performed using mixed model repeated measures.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
Change From Randomization in the Clinical Global Impressions - Bipolar, Severity of Illness (CGI-BP[S]) at Each Visit in the Randomized Phase
Severity of the bipolar illness was based on the CGI-BP(S) score which had a range from 1 (normal, not ill) to 7 (very severely ill). Analysis was performed using mixed model repeated measures.
Time frame: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
Summary of Clinical Global Impressions - Bipolar - Improvement of Illness (CGI-BP [I]) Scores During Open-label Phase
Improvement of bipolar illness was based on the CGI-BP (I) score which ranged from 1 (very much improved) to 7 (very much worse). Analysis was performed using mixed model repeated measures.
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
Summary of Clinical Global Impressions - Bipolar - Improvement of Illness (CGI-BP [I]) Scores During Randomized Phase
Improvement of bipolar illness was based on the CGI-BP(I) score which ranged from 1 (very much improved) to 7 (very much worse). Analysis was performed using mixed model repeated measures.
Time frame: Randomization weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32 and 36
Number of Participants Considered Much Improved or Very Much Improved [Defined as a Clinical Global Impression-Bipolar Version, Improvement of Illness (CGI-BP[I]), Score of 1 or 2] at Each Visit Compared to Baseline in the Open-Label Phase
The CGI-BP(I) asks the following question: "Compared to the Baseline assessment in this trial, how much has the participant changed?". Scores on the CGI-I range from 1 (very much improved) to 7 (very much worse). The investigator or their designee rated improvement regardless of whether the improvement to be due to drug treatment. Improvement defined as CGI-BP(I)=1 (improved) or 2 (very much improved). Missing data imputed using last-observation carried forward (LOCF).
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
Number of Participants Considered Much Improved or Very Much Improved [Defined as a Clinical Global Impression-Bipolar Version, Improvement of Illness (CGI-BP[I]), Score of 1 or 2] at Each Visit Compared to Randomization in the Randomized Phase
The CGI-BP(I) asks the following question: "Compared to the Randomization assessment in this trial, how much has the participant changed?". Scores on the CGI-I range from 1 (very much improved) to 7 (very much worse). The investigator or their designee rated improvement regardless of whether the improvement to be due to drug treatment. Improvement defined as CGI-BP(I)=1 (improved) or 2 (very much improved). Missing data imputed using last-observation carried forward (LOCF).
Time frame: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
Change From Baseline in the Young Mania Rating Scale (YMRS) at Each Visit in the Open-Label Phase
The YMRS consists of 11 items and is based on the participant's report of their mania symptoms. It is clinician rated. Four items (irritability, speech, thought content, and disruptive/aggressive behavior) are rated on a scale of 0 to 8, while the other seven items (elevated mood, increased motor activity-energy, sexual interest, sleep, language, appearance, and insight) are rated on a scale of 0 to 4. The range of scores for the YMRS is 0 (best possible outcome) to 60 (worst possible outcome). The YMRS was completed by the investigator or their qualified designee. Analysis was performed using mixed model repeated measures.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
Change From Randomization in the Young Mania Rating Scale (YMRS) at Each Visit in the Randomized Phase
The YMRS consists of 11 items and is based on the participant's report of their mania symptoms. It is clinician rated. Four items (irritability, speech, thought content, and disruptive/aggressive behavior) are rated on a scale of 0 to 8, while the other seven items (elevated mood, increased motor activity-energy, sexual interest, sleep, language, appearance, and insight) are rated on a scale of 0 to 4. The range of scores for the YMRS is 0 (best possible outcome) to 60 (worst possible outcome). The YMRS was completed by the investigator or their qualified designee. Analysis was performed using mixed model repeated measures.
Time frame: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
Change From Baseline in the Parent Version of the Young Mania Rating Scale (P-YMRS) at Each Visit in the Open-Label Phase
The P-YMRS was adapted from the YMRS for completion by parents of the pediatric participants with bipolar disorder in order to assess the severity of the manic symptoms. The P-YMRS consisted of 11 items and had a total score range of 0 (best possible outcome) to 60 (worst possible outcome). The P-YMRS was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.
Time frame: Baseline and Weeks 4, 8, 12, 16, and 18
Change From Randomization in the Parent Version of the Young Mania Rating Scale (P-YMRS) at Each Visit in the Randomized Phase
The P-YMRS was adapted from the YMRS for completion by parents of the pediatric participants with bipolar disorder in order to assess the severity of the manic symptoms. The P-YMRS consisted of 11 items and had a total score range of 0 (best possible outcome) to 60 (worst possible outcome). The P-YMRS was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.
Time frame: Randomization and Weeks 8, 16, 24, 32, and 36
Change From Baseline in the Conners' Global Index - Parent Version (CGI-P) at Each Visit in the Open-Label Phase
The CGI-P is a 10-item scale used to assess attention deficit hyperactivity disorder (ADHD) symptoms in children and adolescents aged 3-17 years of age. The scale is composed of two factors: restless-impulsive behavior and emotional lability. Each item was scored on a 0-3 scale. The range of scores for the CGI-P is 0 (best possible outcome) to 30 (worst possible outcome). The CGI-P was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.
Time frame: Baseline and Weeks 4, 8, 12, 16, and 18
Change From Randomization in the Conners' Global Index - Parent Version (CGI-P) at Each Visit in the Randomized Phase.
The CGI-P is a 10-item scale used to assess attention deficit hyperactivity disorder (ADHD) symptoms in children and adolescents aged 3-17 years of age. The scale is composed of two factors: restless-impulsive behavior and emotional lability. Each item was scored on a 0-3 scale. The range of scores for the CGI-P is 0 (best possible outcome) to 30 (worst possible outcome). The CGI-P was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.
Time frame: Randomization and Weeks 8, 16, 24, 32, and 36
A total of 301 participants were enrolled in the study, of which 298 subjects took at least one dose of lamotrigine (LTG). One hundred and seventy three participants met stabilization criteria and entered the Randomized Phase.
| Milestone | LTG: Open-Label Phase | Placebo | Lamotrigine |
|---|---|---|---|
| Started | 298 | 0 | 0 |
| Completed | 173 | 0 | 0 |
| Not completed | 125 | 0 | 0 |
| Withdrew: Adverse event | 26 | 0 | 0 |
| Withdrew: Lack of efficacy | 18 | 0 | 0 |
| Withdrew: Protocol violation | 35 | 0 | 0 |
| Withdrew: Lost to follow-up | 7 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 37 | 0 | 0 |
| Milestone | LTG: Open-Label Phase | Placebo | Lamotrigine |
|---|---|---|---|
| Started | 0 | 86 | 87 |
| Completed | 0 | 21 | 20 |
| Not completed | 0 | 65 | 67 |
| Withdrew: Adverse event | 0 | 26 | 17 |
| Withdrew: Lack of efficacy | 0 | 11 | 11 |
| Withdrew: Protocol violation | 0 | 9 | 13 |
| Withdrew: Lost to follow-up | 0 | 2 | 3 |
| Withdrew: Physician decision | 0 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 14 | 22 |
TOBE was defined by the first prescription of any additional pharmacotherapy to treat bipolar symptoms, increasing the dose(s) of the participants conventional bipolar medication(s), treatment with electroconvulsive therapy, or moving the participant to a more restricted environment for observation, safety, or treatment; or participant withdrawal from the study due to a bipolar-related adverse event (AE) or serious adverse event (SAE); or participants withdrawal from the study due to lack of efficacy as defined by rating scale threshold scores. TOBE was calculated using a log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).
| Days | Placebo | Lamotrigine |
|---|---|---|
| Stratum: Depression, n=22,21 | 50 ± 3.8 | 155 ± 14.7 |
| Stratum: Mania/Hypomania, n=36, 37 | 120 ± 12.2 | 163 ± 12.2 |
| Stratum: Mixed Mood, n=28, 29 | 107 ± 13.8 | 136 ± 15.4 |
The time from randomization to the withdrawal from study was analyzed. TTW was calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).
| Days | Placebo | Lamotrigine |
|---|---|---|
| Stratum: Depression, n=22, 21 | 113 ± 21.4 | 141 ± 20.0 |
| Stratum: Mania/Hypomania, n=36, 37 | 138 ± 17.3 | 144 ± 15.6 |
| Stratum: Mixed Mood, n=28, 29 | 101 ± 15.7 | 106 ± 16.3 |
The time from randomization to the intervention for a mood episode (depression, mania/hypomania or mixed mood) was analyzed. TIME was calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).
| Days | Placebo | Lamotrigine |
|---|---|---|
| Stratum: Depression, n=22, 21 | 62 ± 5.2 | 164 ± 12.7 |
| Stratum: Mania/Hypomania, n=36, 37 | 129 ± 11.7 | 179 ± 10.8 |
| Stratum: Mixed Mood, n=28, 29 | 120 ± 13.7 | 127 ± 12.0 |
The time from randomization to intervention for depression (TIDep), mania/hypomania (TIMan), or a mixed episode (TIMix) was analyzed. TIDep, TIMan, and TIMix were calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).
| Days | Placebo | Lamotrigine |
|---|---|---|
| TIDep: Depression, n=22, 21 | 61 ± 1.5 | 46 ± 1.5 |
| TIDep: Mania/Hypomania, n=36, 37 | NA ± NA | NA ± NA |
| TIDep: Mixed Mood, n=28, 29 | 59 ± 2.6 | 159 ± NA |
| TIMan: Depression, n=22, 21 | 74 ± 3.9 | 182 ± NA |
| TIMan: Mania/Hypomania, n=36, 37 | 139 ± 11.5 | 61 ± 2.1 |
| TIMan: Mixed Mood, n=28, 29 | 105 ± 7.3 | 148 ± 8.5 |
| TIMix: Depression, n=22, 21 | 37 ± 1.3 | 158 ± NA |
| TIMix: Mania/Hypomania, n=36, 37 | 135 ± 6.3 | 194 ± 7.5 |
| TIMix: Mixed Mood, n=28, 29 | 160 ± 10.7 | 57 ± 2.5 |
The number of participants requiring intervention to treat either the emergence of or a change in bipolar symptoms that is, experiencing a relapse/recurrence to depression, mania/hypomania, or mixed mood state were analyzed.
| Participants | Placebo | Lamotrigine |
|---|---|---|
| Depression | 5 | 3 |
| Mania/hypomania | 16 | 6 |
| Mixed episode state | 10 | 9 |
The proportion of participants (par.) requiring intervention to treat either the emergence of or a change in bipolar symptoms, that is, experiencing a relapse/recurrence to depression, mania/hypomania, or mixed mood state at any time within the first 30, 90, and 180 days in the Randomized Phase were analyzed.
| Participants | Placebo | Lamotrigine |
|---|---|---|
| Mania/hypomania, 30 days, n=16, 6 | 9 | 2 |
| Mania/hypomania, 90 days, n=16, 6 | 12 | 4 |
| Mania/hypomania, 180 days, n=16, 6 | 16 | 5 |
| Depression, 30 days, n=5, 3 | 1 | 1 |
| Depression, 90 days, n=5, 3 | 5 | 2 |
| Depression, 180 days, n=5, 3 | 5 | 3 |
| Mixed mood state, 30 days, n= 10, 9 | 3 | 2 |
| Mixed mood state, 90 days, n= 10, 9 | 7 | 6 |
| Mixed mood state, 180 days, n= 10, 9 | 10 | 8 |
The QIDS-A17-C is a 17-item scale used to assess depression severity in adolescents according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). Analysis was performed using mixed model repeated measures.
| Scores on a Scale | LTG: Open-Label Phase |
|---|---|
| Week 1 | -2.1 ± 0.22 |
| Week 2 | -2.9 ± 0.28 |
| Week 3 | -3.7 ± 0.28 |
| Week 4 | -3.8 ± 0.30 |
| Week 5 | -4.3 ± 0.30 |
| Week 6 | -4.7 ± 0.30 |
| Week 7 | -5.1 ± 0.30 |
| Week 8 | -4.9 ± 0.31 |
| Week 9 | -5.6 ± 0.30 |
| Week 10 | -6.1 ± 0.29 |
| Week 11 | -6.4 ± 0.30 |
| Week 12 | -6.6 ± 0.32 |
| Week 13 | -6.7 ± 0.32 |
| Week 14 | -6.8 ± 0.34 |
| Week 15 | -6.8 ± 0.40 |
| Week 16 | -6.8 ± 0.41 |
| Week 17 | -6.5 ± 0.53 |
| Week 18 | -6.5 ± 0.70 |
The QIDS-A17-C is a 17-item scale used to assess depression severity in adolescents according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). Analysis was performed using mixed model repeated measures.
| Scores on a scale | Placebo | Lamotrigine |
|---|---|---|
| Week 1 | 0.8 ± 0.30 | 0.5 ± 0.31 |
| Week 2 | 1.5 ± 0.37 | 1.1 ± 0.37 |
| Week 3 | 1.3 ± 0.36 | 0.6 ± 0.36 |
| Week 4 | 1.2 ± 0.39 | 1.0 ± 0.39 |
| Week 6 | 1.9 ± 0.49 | 1.5 ± 0.47 |
| Week 8 | 1.9 ± 0.47 | 1.7 ± 0.45 |
| Week 10 | 1.4 ± 0.44 | 1.5 ± 0.41 |
| Week 12 | 1.4 ± 0.40 | 1.2 ± 0.39 |
| Week 16 | 2.2 ± 0.48 | 1.8 ± 0.47 |
| Week 20 | 1.5 ± 0.50 | 2.5 ± 0.46 |
| Week 24 | 1.7 ± 0.53 | 1.8 ± 0.51 |
| Week 28 | 1.6 ± 0.61 | 2.3 ± 0.57 |
| Week 32 | 1.0 ± 0.72 | 1.9 ± 0.72 |
| Week 36 | 2.3 ± 0.63 | 1.9 ± 0.63 |
The QIDS-A17-SR is a 17-item scale used to assess depression severity in adolescents according to the DSM-IV-TR diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). The scale is completed by the participant. Analysis was performed using mixed model repeated measures.
| Scores on a scale | LTG: Open-Label Phase |
|---|---|
| Week 4 | -2.7 ± 0.25 |
| Week 8 | -3.3 ± 0.27 |
| Week 12 | -4.3 ± 0.28 |
| Week 16 | -4.5 ± 0.33 |
| Week 18 | -5.0 ± 0.52 |
The QIDS-A17-SR is a 17-item scale used to assess depression severity in adolescents according to the DSM-IV-TR diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). The scale is completed by the participant. Analysis was performed using mixed model repeated measures.
| Scores on a scale | Placebo | Lamotrigine |
|---|---|---|
| Week 8 | 1.6 ± 0.47 | 1.2 ± 0.48 |
| Week 16 | 1.6 ± 0.60 | 1.4 ± 0.58 |
| Week 24 | 1.0 ± 0.60 | 1.5 ± 0.56 |
| Week 32 | 0.6 ± 0.66 | 0.2 ± 0.63 |
| Week 36 | 0.9 ± 0.66 | 0.8 ± 0.68 |
Severity of the bipolar illness was based on the CGI-BP(S) score which had a range from 1 (normal, not ill) to 7 (very severely ill). Analysis was performed using mixed model repeated measures.
| Scores on a scale | LTG: Open-Label Phase |
|---|---|
| Week 1 | -0.4 ± 0.05 |
| Week 2 | -0.6 ± 0.05 |
| Week 3 | -0.9 ± 0.06 |
| Week 4 | -1.0 ± 0.06 |
| Week 5 | -1.2 ± 0.06 |
| Week 6 | -1.3 ± 0.06 |
| Week 7 | -1.4 ± 0.07 |
| Week 8 | -1.5 ± 0.07 |
| Week 9 | -1.6 ± 0.07 |
| Week 10 | -1.8 ± 0.07 |
| Week 11 | -1.9 ± 0.07 |
| Week 12 | -2.1 ± 0.07 |
| Week 13 | -2.1 ± 0.07 |
| Week 14 | -2.1 ± 0.07 |
| Week 15 | -2.1 ± 0.08 |
| Week 16 | -2.1 ± 0.10 |
| Week 17 | -2.0 ± 0.12 |
| Week 18 | -2.1 ± 0.15 |
Severity of the bipolar illness was based on the CGI-BP(S) score which had a range from 1 (normal, not ill) to 7 (very severely ill). Analysis was performed using mixed model repeated measures.
| Scores on a scale | Placebo | Lamotrigine |
|---|---|---|
| Week 1 | 0.2 ± 0.09 | 0.0 ± 0.09 |
| Week 2 | 0.4 ± 0.12 | 0.2 ± 0.12 |
| Week 3 | 0.4 ± 0.12 | 0.2 ± 0.12 |
| Week 4 | 0.6 ± 0.13 | 0.3 ± 0.13 |
| Week 6 | 0.8 ± 0.15 | 0.4 ± 0.15 |
| Week 8 | 0.7 ± 0.15 | 0.4 ± 0.14 |
| Week 10 | 0.4 ± 0.13 | 0.6 ± 0.13 |
| Week 12 | 0.5 ± 0.14 | 0.4 ± 0.14 |
| Week 16 | 0.6 ± 0.17 | 0.6 ± 0.15 |
| Week 20 | 0.5 ± 0.17 | 0.8 ± 0.16 |
| Week 24 | 0.4 ± 0.17 | 0.6 ± 0.16 |
| Week 28 | 0.3 ± 0.17 | 0.5 ± 0.16 |
| Week 32 | 0.2 ± 0.19 | 0.5 ± 0.20 |
| Week 36 | 0.4 ± 0.19 | 0.3 ± 0.21 |
Improvement of bipolar illness was based on the CGI-BP (I) score which ranged from 1 (very much improved) to 7 (very much worse). Analysis was performed using mixed model repeated measures.
| Scores on a scale | LTG: Open-Label Phase |
|---|---|
| Week 1, n=290 | 3.6 ± 0.80 |
| Week 2, n=278 | 3.3 ± 0.90 |
| Week 3, n=270 | 3.1 ± 0.96 |
| Week 4, n=265 | 3.0 ± 1.03 |
| Week 5, n=258 | 2.8 ± 1.01 |
| Week 6, n=243 | 2.7 ± 1.05 |
| Week 7, n=246 | 2.5 ± 1.07 |
| Week 8, n=236 | 2.5 ± 1.09 |
| Week 9, n=227 | 2.3 ± 1.05 |
| Week 10, n=205 | 2.2 ± 1.09 |
| Week 11, n=181 | 2.2 ± 0.92 |
| Week 12, n=168 | 2.0 ± 0.87 |
| Week 13, n=141 | 1.9 ± 0.85 |
| Week 14, n=118 | 1.9 ± 0.69 |
| Week 15, n=93 | 1.8 ± 0.71 |
| Week 16, n=72 | 2.0 ± 0.89 |
| Week 17, n=42 | 2.0 ± 0.70 |
| Week 18, n=28 | 2.0 ± 0.88 |
Improvement of bipolar illness was based on the CGI-BP(I) score which ranged from 1 (very much improved) to 7 (very much worse). Analysis was performed using mixed model repeated measures.
| Scores on a scale | Placebo | Lamotrigine |
|---|---|---|
| Week 1, n=84, 85 | 3.3 ± 1.40 | 3.3 ± 1.37 |
| Week 2, n=82, 81 | 3.7 ± 1.48 | 3.6 ± 1.38 |
| Week 3, n=74, 75 | 3.6 ± 1.39 | 3.6 ± 1.34 |
| Week 4, n=65, 70 | 3.6 ± 1.51 | 3.6 ± 1.35 |
| Week 6, n=58, 64 | 3.8 ± 1.64 | 3.4 ± 1.49 |
| Week 8, n=51, 60 | 3.5 ± 1.72 | 3.6 ± 1.47 |
| Week 10, n=45, 55 | 3.3 ± 1.64 | 3.8 ± 1.19 |
| Week 12, n=45, 49 | 3.3 ± 1.52 | 3.4 ± 1.29 |
| Week 16, n=43, 50 | 3.4 ± 1.73 | 3.5 ± 1.37 |
| Week 20, n=37, 43 | 3.0 ± 1.48 | 3.8 ± 1.36 |
| Week 24, n=34, 36 | 3.0 ± 1.59 | 3.4 ± 1.44 |
| Week 28, n=29, 32 | 2.7 ± 1.56 | 3.5 ± 1.44 |
| Week 32, n=28, 27 | 3.0 ± 1.63 | 3.5 ± 1.28 |
| Week 36, n=27, 24 | 3.0 ± 1.68 | 3.6 ± 1.10 |
The CGI-BP(I) asks the following question: "Compared to the Baseline assessment in this trial, how much has the participant changed?". Scores on the CGI-I range from 1 (very much improved) to 7 (very much worse). The investigator or their designee rated improvement regardless of whether the improvement to be due to drug treatment. Improvement defined as CGI-BP(I)=1 (improved) or 2 (very much improved). Missing data imputed using last-observation carried forward (LOCF).
| Participants | LTG: Open-Label Phase |
|---|---|
| Week 1, n=297 | 27 |
| Week 2, n=297 | 46 |
| Week 3, n=297 | 72 |
| Week 4, n=297 | 86 |
| Week 5, n=297 | 113 |
| Week 6, n=297 | 124 |
| Week 7, n=297 | 138 |
| Week 8, n=297 | 140 |
| Week 9, n=297 | 159 |
| Week 10, n=297 | 176 |
| Week 11, n=297 | 182 |
| Week 12, n=297 | 195 |
| Week 13, n=297 | 205 |
| Week 14, n=297 | 211 |
| Week 15, n=297 | 210 |
| Week 16, n=297 | 209 |
| Week 17, n=297 | 208 |
| Week 18, n=297 | 206 |
The CGI-BP(I) asks the following question: "Compared to the Randomization assessment in this trial, how much has the participant changed?". Scores on the CGI-I range from 1 (very much improved) to 7 (very much worse). The investigator or their designee rated improvement regardless of whether the improvement to be due to drug treatment. Improvement defined as CGI-BP(I)=1 (improved) or 2 (very much improved). Missing data imputed using last-observation carried forward (LOCF).
| Participants | Placebo | Lamotrigine |
|---|---|---|
| Week 1 | 31 | 31 |
| Week 2 | 25 | 22 |
| Week 3 | 24 | 21 |
| Week 4 | 22 | 19 |
| Week 6 | 20 | 23 |
| Week 8 | 22 | 19 |
| Week 10 | 22 | 12 |
| Week 12 | 21 | 17 |
| Week 16 | 21 | 16 |
| Week 20 | 21 | 14 |
| Week 24 | 21 | 15 |
| Week 28 | 22 | 15 |
| Week 32 | 19 | 15 |
| Week 36 | 20 | 13 |
The YMRS consists of 11 items and is based on the participant's report of their mania symptoms. It is clinician rated. Four items (irritability, speech, thought content, and disruptive/aggressive behavior) are rated on a scale of 0 to 8, while the other seven items (elevated mood, increased motor activity-energy, sexual interest, sleep, language, appearance, and insight) are rated on a scale of 0 to 4. The range of scores for the YMRS is 0 (best possible outcome) to 60 (worst possible outcome). The YMRS was completed by the investigator or their qualified designee. Analysis was performed using mixed model repeated measures.
| Scores on a scale | LTG: Open-Label Phase |
|---|---|
| Week 1 | -3.2 ± 0.39 |
| Week 2 | -4.8 ± 0.42 |
| Week 3 | -6.4 ± 0.45 |
| Week 4 | -6.5 ± 0.46 |
| Week 5 | -7.5 ± 0.50 |
| Week 6 | -8.4 ± 0.50 |
| Week 7 | -9.1 ± 0.51 |
| Week 8 | -8.8 ± 0.48 |
| Week 9 | -9.6 ± 0.48 |
| Week 10 | -10.3 ± 0.49 |
| Week 11 | -11.1 ± 0.48 |
| Week 12 | -11.6 ± 0.53 |
| Week 13 | -12.0 ± 0.58 |
| Week 14 | -12.0 ± 0.59 |
| Week 15 | -12.4 ± 0.63 |
| Week 16 | -12.3 ± 0.78 |
| Week 17 | -12.2 ± 0.88 |
| Week 18 | -12.1 ± 1.43 |
The YMRS consists of 11 items and is based on the participant's report of their mania symptoms. It is clinician rated. Four items (irritability, speech, thought content, and disruptive/aggressive behavior) are rated on a scale of 0 to 8, while the other seven items (elevated mood, increased motor activity-energy, sexual interest, sleep, language, appearance, and insight) are rated on a scale of 0 to 4. The range of scores for the YMRS is 0 (best possible outcome) to 60 (worst possible outcome). The YMRS was completed by the investigator or their qualified designee. Analysis was performed using mixed model repeated measures.
| Scores on a scale | Placebo | Lamotrigine |
|---|---|---|
| Week 1 | 1.3 ± 0.57 | 0.4 ± 0.59 |
| Week 2 | 2.6 ± 0.72 | 2.1 ± 0.72 |
| Week 3 | 2.6 ± 0.69 | 1.3 ± 0.71 |
| Week 4 | 3.7 ± 0.85 | 2.0 ± 0.84 |
| Week 6 | 4.9 ± 0.96 | 2.3 ± 0.93 |
| Week 8 | 4.3 ± 0.98 | 3.5 ± 0.93 |
| Week 10 | 3.5 ± 0.87 | 2.9 ± 0.82 |
| Week 12 | 3.2 ± 0.84 | 1.6 ± 0.81 |
| Week 16 | 4.7 ± 0.93 | 3.0 ± 0.89 |
| Week 20 | 4.8 ± 0.99 | 4.5 ± 0.92 |
| Week 24 | 4.2 ± 1.06 | 2.9 ± 1.02 |
| Week 28 | 4.4 ± 1.04 | 3.7 ± 1.01 |
| Week 32 | 4.5 ± 1.10 | 2.6 ± 1.14 |
| Week 36 | 3.5 ± 0.92 | 1.2 ± 0.95 |
The P-YMRS was adapted from the YMRS for completion by parents of the pediatric participants with bipolar disorder in order to assess the severity of the manic symptoms. The P-YMRS consisted of 11 items and had a total score range of 0 (best possible outcome) to 60 (worst possible outcome). The P-YMRS was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.
| Scores on a scale | LTG: Open-Label Phase |
|---|---|
| Week 4 | -4.7 ± 0.57 |
| Week 8 | -6.0 ± 0.62 |
| Week 12 | -7.4 ± 0.62 |
| Week 16 | -8.2 ± 0.72 |
| Week 18 | -9.3 ± 1.29 |
The P-YMRS was adapted from the YMRS for completion by parents of the pediatric participants with bipolar disorder in order to assess the severity of the manic symptoms. The P-YMRS consisted of 11 items and had a total score range of 0 (best possible outcome) to 60 (worst possible outcome). The P-YMRS was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.
| Scores on a scale | Placebo | Lamotrigine |
|---|---|---|
| Week 8 | 4.9 ± 0.93 | 4.3 ± 0.95 |
| Week 16 | 2.7 ± 1.13 | 2.6 ± 1.09 |
| Week 24 | 5.3 ± 1.35 | 5.7 ± 1.29 |
| Week 32 | 5.1 ± 1.33 | 6.0 ± 1.32 |
| Week 36 | 5.3 ± 1.33 | 4.5 ± 1.36 |
The CGI-P is a 10-item scale used to assess attention deficit hyperactivity disorder (ADHD) symptoms in children and adolescents aged 3-17 years of age. The scale is composed of two factors: restless-impulsive behavior and emotional lability. Each item was scored on a 0-3 scale. The range of scores for the CGI-P is 0 (best possible outcome) to 30 (worst possible outcome). The CGI-P was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.
| Scores on a scale | LTG: Open-Label Phase |
|---|---|
| Week 4 | -4.0 ± 0.36 |
| Week 8 | -5.7 ± 0.43 |
| Week 12 | -6.7 ± 0.47 |
| Week 16 | -7.1 ± 0.56 |
| Week 18 | -8.2 ± 1.07 |
The CGI-P is a 10-item scale used to assess attention deficit hyperactivity disorder (ADHD) symptoms in children and adolescents aged 3-17 years of age. The scale is composed of two factors: restless-impulsive behavior and emotional lability. Each item was scored on a 0-3 scale. The range of scores for the CGI-P is 0 (best possible outcome) to 30 (worst possible outcome). The CGI-P was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.
| Scores on a scale | Placebo | Lamotrigine |
|---|---|---|
| Week 8 | 3.1 ± 0.75 | 2.1 ± 0.77 |
| Week 16 | 3.4 ± 0.92 | 1.2 ± 0.90 |
| Week 24 | 2.4 ± 1.12 | 3.1 ± 1.05 |
| Week 32 | 2.7 ± 1.10 | 2.6 ± 1.08 |
| Week 36 | 1.5 ± 1.00 | 0.5 ± 1.03 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the first dose of investigational product until the last visit of the Open-Label or Double-Blind Taper and Follow-up Phase (up to Taper Week 4).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-Label and Open-Label Taper Phases: LTG | — | 19/298 (6.4%) | 177/298 (59.4%) |
| Randomized and Double-blind Taper Phases: Placebo | — | 5/86 (5.8%) | 41/86 (47.7%) |
| Randomized and Double-blind Taper Phases: LTG | — | 1/87 (1.1%) | 45/87 (51.7%) |
| Event | Open-Label and Open-Label Taper Phases: LTG | Randomized and Double-blind Taper Phases: Placebo | Randomized and Double-blind Taper Phases: LTG |
|---|---|---|---|
| Suicidal ideationPsychiatric disorders | 5/298 | 1/86 | 0/87 |
| ManiaPsychiatric disorders | 3/298 | 1/86 | 0/87 |
| Bipolar I disorderPsychiatric disorders | 1/298 | 1/86 | 0/87 |
| Infectious mononucleosisInfections and infestations | 0/298 | 1/86 | 0/87 |
| Urinary tract infectionInfections and infestations | 0/298 | 1/86 | 0/87 |
| Intentional overdoseInjury, poisoning and procedural complications | 0/298 | 1/86 | 0/87 |
| Emotional disorderPsychiatric disorders | 0/298 | 0/86 | 1/87 |
| AgitationPsychiatric disorders | 3/298 | 0/86 | 0/87 |
| IrritabilityGeneral disorders | 2/298 | 0/86 | 0/87 |
| AggressionPsychiatric disorders | 1/298 | 0/86 | 0/87 |
| Event | Open-Label and Open-Label Taper Phases: LTG | Randomized and Double-blind Taper Phases: Placebo | Randomized and Double-blind Taper Phases: LTG |
|---|---|---|---|
| HeadacheNervous system disorders | 106/298 | 18/86 | 18/87 |
| IrritabilityGeneral disorders | 16/298 | 14/86 | 7/87 |
| Abdominal pain upperGastrointestinal disorders | 47/298 | 3/86 | 5/87 |
| NauseaGastrointestinal disorders | 39/298 | 0/86 | 0/87 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 30/298 | 2/86 | 7/87 |
| VomitingGastrointestinal disorders | 25/298 | 3/86 | 5/87 |
| NasopharyngitisInfections and infestations | 25/298 | 5/86 | 7/87 |
| DizzinessNervous system disorders | 24/298 | 0/86 | 0/87 |
| InfluenzaInfections and infestations | 0/298 | 2/86 | 7/87 |
| CoughRespiratory, thoracic and mediastinal disorders | 21/298 | 4/86 | 7/87 |
| Age, Continuous(Years) | Placebo | Lamotrigine | Total |
|---|---|---|---|
| Mean | 13.5 ± 2.22 | 13.4 ± 2.33 | 13.5 ± 2.27 |
| Gender(Participants) | Placebo | Lamotrigine | Total |
|---|---|---|---|
| Female | 39 | 33 | 72 |
| Male | 47 | 54 | 101 |
| Race/Ethnicity, Customized(Participants) | Placebo | Lamotrigine | Total |
|---|---|---|---|
| African American/African Heritage | 9 | 9 | 18 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian - East Asian Heritage | 1 | 0 | 1 |
| White - Arabic/North African Heritage | 1 | 0 | 1 |
| White - White/Caucasian/European Heritage | 71 | 71 | 142 |
| Mixed Race | 4 | 6 | 10 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jul 2008, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamotrigine